In the genomes of specific cancers, namely breast, head-and-neck, liver, lung adenocarcinoma, squamous cell lung cancer, and melanomas, PAK5 frequently carries non-synonymous point mutations, and small insertions and deletions; PAK6 and PAK4 have fewer; and PAK4 is often amplified. This evidence concerns the gene PAK6 and melanoma.